# Febuxostat voor cerebraal en cardiorenovasculaire eventpreventie: FREED

*geplaatst 2019-06-07 · Preventie · European heart journal · doi 10.1093/eurheartj/ehz119 · https://hartvaat.nl/2019/06/07/febuxostat-voor-cerebraal-en-cardiorenovasculaire-eventpreventie-freed/*

FREED-studie naar febuxostat voor preventie van cerebrovasculaire en cardiorenale events. Onderzoekt urinezuurverlaging als preventieve strategie.

## English: Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.

The FREED study compared febuxostat with conventional treatment for hyperuricemia on cerebrovascular, cardiovascular, and renal events, testing the hypothesis that uric acid lowering provides vascular protection.

## Abstract (original, from the publication)

AIMS: To compare the occurrence of cerebral, cardiovascular, and renal events in patients with hyperuricaemia treated with febuxostat and those treated with conventional therapy with lifestyle modification. METHODS AND RESULTS: This multicentre, prospective, randomized open-label, blinded endpoint study was done in 141 hospitals in Japan. A total of 1070 patients were included in the intention-to-treat population. Elderly patients with hyperuricaemia (serum uric acid >7.0 to ≤9.0 mg/dL) at risk for cerebral, cardiovascular, or renal disease, defined by the presence of hypertension, Type 2 diabetes, renal disease, or history of cerebral or cardiovascular disease, were randomized to febuxostat and non-febuxostat groups and were observed for 36 months. Cerebral, cardiovascular, and renal events and all deaths were defined as the primary composite event. The serum uric acid level at endpoint (withdrawal or completion of the study) in the febuxostat (n = 537) and non-febuxostat groups (n = 533) was 4.50 ± 1.52 and 6.76 ± 1.45 mg/dL, respectively (P < 0.001). The primary composite event rate was significantly lower in the febuxostat group than in non-febuxostat treatment [hazard ratio (HR) 0.750, 95% confidence interval (CI) 0.592-0.950; P = 0.017] and the most frequent event was renal impairment (febuxostat group: 16.2%, non-febuxostat group: 20.5%; HR 0.745, 95% CI 0.562-0.987; P = 0.041). CONCLUSION: Febuxostat lowers uric acid and delays the progression of renal dysfunction. REGISTRATION: ClinicalTrials.gov (NCT01984749).

Auteurs: Sunao Kojima, Kunihiko Matsui, Shinya Hiramitsu, Ichiro Hisatome, Masako Waki, Kazuaki Uchiyama, Naoto Yokota, Eiichi Tokutake, Yutaka Wakasa, Hideaki Jinnouchi, Hirokazu Kakuda, Takahiro Hayashi, Naoki Kawai, Hisao Mori, Masahiro Sugawara, Yusuke Ohya, Kazuo Kimura, Yoshihiko Saito, Hisao Ogawa

---
Bron: European heart journal, https://doi.org/10.1093/eurheartj/ehz119. Bijgewerkt 2026-07-03T13:27:10Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.